

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	ATTY.'S DOCKET: NOZAKI=8.1A
In re Application of:) Confirmation No. 3949
Masako NOZAKI) Art Unit: 1614
Appln. No.: 10/721,742) Examiner:
Filed: November 26, 2003) Washington, D.C.
For: METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS) September 23, 2004))

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Amendment Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

Before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either

In re Appln. No. 10/721,742

incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

Document(s) <u>AD-AF</u> are U.S. patent(s) and/or published application(s). As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 U.S.C. §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (MPEP §609IIIA(2)(A)).

- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. Other information being provided for the examiner's consideration follows:

Attached is a copy of the Partial European Search Report

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made & that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys fom Applicant(s)

By:

Allen C. Yun Reg. No. 37,971

ACY:pp

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197
Facsimile: (202)737-3528
G:\BN\N\noza\nozaki8.1A\pto\3rd IDS.doc

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 10/721,742

Filing Date November 26, 2003

First Named Inventor Masako NOZAKI

Group Art Unit 1614

Examiner Name

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number NOZAKI=8.1A

SEP 2 4 2004

4	U.S. PATENT DOCUMENTS					
Examiner			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*				****	Figures Appear	
	AD	US-2002/0123520 A1	09-05-2002	MARFAT et al.		
	AE	US-5,441,951	08-15-1995	SERHAN		
	AF	US-5,079,261	01-07-1992	SERHAN et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	AG	EP 0905133 A1	03-31-1999	KOWA CO. LTD.				
	АН	EP 0528337 A1	02-24-1993	FUJISAWA PHARMACEUTICAL CO., LTD.				
	Al	EP 0351856 A2	01-24-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.				
	AJ	EP 1424101 A2	06-02-2004	NOZAKI				
	AK	WO 99/21007	04-29-1999	PHARMAPRINT, INC.				
	AL	WO 02/060875 A1	08-08-2002	PFIZER PRODUCTORS INC.				

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²			
	AM	ALVAREZ LOSADA, Role of platelet-activating factor, eicosanoids and bradykinin in adjuvant therapy for sepsis, Acta Perdiatrica Espanola. 60(9):535-544 (2002)	ABS			
	AN	BEERS AND BERKOW, Merck manual of diagnosis and therapy, Merck Research Laboratories, 1435-1437 (1999)				
	AO	KOBAYASHI et al., Effect of leukotriene antagonist on experimental delayed cerebral vasospasm, Neurosurgery, 31(3):550-556 (1992)				
	AP	MATSUO et al., Leukotriene B ₄ and C ₄ in cerebrospinal fluid from children with meningitis and febrile seizures, Pediatric Neurology, 14(2):121-124 (1996)				
	AQ	NEUWELT et al., Use of enhanced computerized tomography to evaluate osmotic blood-brain barrier disruption, Neurosurgery, 6(1):49-56 (1980)				
	AR	OGATA et al., Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice, <u>Infection and Immunity</u> , 60(6):2432-2437 (1992)				
	AS	YOSHIKAWA et al., Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte, <u>Circulatory Shock</u> , 38:29-33 (1992)				
	АТ	Is there a therapeutic role for blood-brain barrier disruption? Annals of Internal Medicine, 93(1):137-139 (1980)				
	AU	Abstract- XP002284974 - Derwent Publications Ltd., (1996)				

Examiner	Date	
Signature	 Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.